Summit is seeking a highly skilled and experienced Medical Affairs Director to lead the medical strategy and tactical execution for the development and launch of ivonescimab in lung-related indications.
About Ivonescimab : Ivonescimab, known as SMT112, is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule.
Ivonescimab displays unique cooperative binding to each of its intended targets with multifold higher affinity when in the presence of both PD-1 and VEGF. Summit has begun its clinical development of ivonescimab in non-small cell lung cancer (NSCLC), with three active Phase III trials :
- HARMONi is a Phase III clinical trial which intends to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a 3rd generation EGFR TKI (e.g., osimertinib).
- HARMONi-3 is a Phase III clinical trial which is designed to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC.
- HARMONi-7 is a Phase III clinical trial which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC whose tumors have high PD-L1 expression.
Key Responsibilities : The successful candidate will be responsible for leading the medical strategy for the launch of ivonescimab in lung-related indications, developing and implementing pre-launch disease and product education programs, and ensuring the medical strategy and its execution align with regulatory requirements.
Drug Launch Leadership : Lead the medical strategy for the launch of ivonescimab in lung-related indications.Pre-Launch Education : Develop and implement pre-launch disease and product education programs for healthcare professionals, patients, and other stakeholders.Medical Strategy Development : Develop and implement medical strategies for ivonescimab in lung-related indications.Regulatory and Compliance Alignment : Work closely with regulatory affairs to ensure compliance with all regulatory requirements.Stakeholder Engagement : Build and maintain relationships with key opinion leaders, healthcare professionals, and other stakeholders.Data Analysis and Interpretation : Analyze and interpret clinical data to provide medical insights and support decision-making processes.Cross-Functional Collaboration : Collaborate with cross-functional teams to ensure the medical strategy supports commercial objectives.Medical Information : Provide accurate and up-to-date medical information to internal and external stakeholders.Compliance : Ensure all activities are conducted in compliance with relevant laws, regulations, and company policies.Experience, Education, and Specialized Knowledge and Skills : The ideal candidate will have an MD, PhD, or PharmD, with a minimum of 10+ years of oncology-related experience in a medical affairs or combination of medical affairs and clinical development role.
Oncology drug launch experience required; lung cancer launch experience is highly preferred.Proven track record in leading medical strategies and supporting launch and on-market oncology therapies.Strong analytical and problem-solving skills with the ability to interpret complex scientific data.Excellent communication and collaboration skills.#J-18808-Ljbffr